Sharp Clinical Launches CDMO Podcast Series to Address Drug Development Challenges
核心洞察
Sharp Clinical (搜索) has launched "Our Experience is Your Strength," a podcast series featuring seasoned experts discussing formulation, sterile manufacturing, clinical supplies, and commercial packaging challenges.
The series emphasizes that successful clinical trial timelines require comprehensive planning, with experts noting that "the secret to speed is planning" when working backwards from ambitious deadlines.
Episode discussions cover critical topics including API formulation development, clinical supply chain management, and the importance of cross-departmental coordination to avoid stockouts and delays.
Sharp Clinical (搜索) has launched a comprehensive podcast series titled "Our Experience is Your Strength," bringing together seasoned experts to address critical challenges in drug development and commercialization through contract development and manufacturing organization (CDMO) services.
The series, hosted by Steve Jacobs, features experts in formulation, sterile manufacturing, clinical supplies, commercial packaging, and sustainability, drawing upon Sharp's decades of experience as a CDMO to help sponsors navigate complex development pathways.
Formulation Development Insights
In the inaugural episode, Devin Corson, Senior Formulation Scientist at Sharp Clinical (搜索), explores the complexities of small molecule formulation development and scale-up processes. Corson emphasizes the inherent uncertainties in early-stage development, stating, "When we're working with an active pharmaceutical ingredient, there's so much that is unknown. We really have no idea how it's going to affect different parts of the body and how it's going to interact with different excipients."
The episode addresses critical considerations for API bioavailability, stability, toxicology, and excipient compatibility, highlighting the importance of allowing sufficient time for optimization despite the excitement to commence clinical trials.
Clinical Supply Chain Management
The third episode features Melissa Peirsel and Sean McCaig, who tackle the critical issue of clinical supply management and timing. Their discussion centers on avoiding stockouts, bottlenecks, and unexpected delays as studies progress from protocol development to patient enrollment.
McCaig emphasizes the importance of organizational alignment, noting, "You need buy-in across departments. Quality assurance, label control, packaging, all have to move together if you want to meet compressed deadlines." The experts stress that while clients often approach CDMOs with ambitious 'first patient in' timelines, success requires working backwards and building adequate time for every step, from label translation to comparator sourcing.
Addressing Complex Trial Designs
The podcast addresses particular challenges associated with rare diseases (搜索), orphan drugs (搜索), and adaptive trial designs, where protocol changes mid-trial can significantly impact supply chain management. Peirsel and McCaig provide insights into managing these complexities while maintaining quality, compliance, and operational efficiency.
Sharp's approach includes implementing just-in-time strategies and integrated Interactive Response Technology (IRT) systems to help sponsors maintain flexibility, reduce waste, and mitigate risks associated with overestimated enrollment figures. The discussion covers push versus pull models, auxiliary labeling requirements, and resupply triggers as key components of effective clinical supply management.
Strategic Planning Philosophy
A central theme throughout the series is the principle that "the secret to speed is planning." This philosophy challenges the common assumption that faster timelines automatically lead to better outcomes, instead advocating for comprehensive upfront planning to achieve both speed and quality in drug development processes.
The podcast series represents Sharp's commitment to sharing practical insights gained through years of CDMO operations, helping sponsors make informed decisions when selecting and working with contract service providers across various stages of drug development and commercialization.